Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study

Topal, İlteriş Oğuz; Baysak, Sevim; Altunay, İlknur Kıvanç; Polat, Asude Kara; Arıkan, Eylem Emel; Özkur, Ezgi; Aytekin, Sema; Doğan, Bilal; Akbulut, Tuğba Özkök; Demir, Filiz Topaloğlu; Karadağ, Ayşe Serap

doi:10.1016/j.abd.2021.11.002

Cited by 4 publications

(2 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is indeed correct as the treatment to reduce the inflammation of psoriasis such as biologics can be implemented by blocking specific inflammatory cytokines produced by T cells (Baliwag et al, 2015; Mohd Noor et al, 2022). While biologics remain the most superior treatment for psoriasis, the side effects still can cause a devastating drawback that often comes with a refractory episode of psoriasis in which the patients may experience relapse episodes of paresthesia on the flaky skin, uncomfortable pain, and itchiness (Topal et al, 2022). In contrast, B cells involvement in psoriasis is considered uncommon due to the rare appearance of B cells in lesional psoriatic skin, hence dismissed.…”

Section: The Involvement Of B Cells In Psoriasismentioning

confidence: 99%

The immunological understanding on germinal center B cells in psoriasis

Noor,

Nor,

Redzwan

2024

Journal Cellular Physiology

View full text Add to dashboard Cite

The development of psoriasis is mainly driven by the dysregulation of T cells within the skin, marking a primary involvement of these cells in the pathogenesis. Although B cells are integral components of the immune system, their role in the initiation and progression of psoriasis is not as pivotal as that of T cells. The paradox of B cell suggests that, while it is crucial for adaptive immunity, B cells may contribute to the exacerbation of psoriasis. Numerous ideas proposed that there are potential relationships between psoriasis and B cells especially within germinal centers (GCs). Recent research projected that B cells might be triggered by autoantigens which then induced molecular mimicry to alter B cells activity within GC and generate autoantibodies and pro‐inflammatory cytokines, form ectopic GC, and dysregulate the proliferation of keratinocytes. Hence, in this review, we gathered potential evidence indicating the participation of B cells in psoriasis within the context of GC, aiming to enhance our comprehension and advance treatment strategies for psoriasis thus inviting many new researchers to investigate this issue.

show abstract

Section: The Involvement Of B Cells In Psoriasismentioning

confidence: 99%

The immunological understanding on germinal center B cells in psoriasis

Noor,

Nor,

Redzwan

2024

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…No safety concerns were identified. Adverse effects occurring in patients treated with secukinumab for psoriasis include the following: Candida infections, erosio interdigitalis blastomycetica, fatigue, nasopharyngitis, paradoxical arthritis, bronchitis, arthralgia, pruritus, and weight gain [ 104 ].…”

Section: Potential and Current Drug Targetsmentioning

confidence: 99%

Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets

Cieplińska,

Niedziela,

Kowalska

2023

JCM

View full text Add to dashboard Cite

Thyroid eye disease (TED) is an extrathyroidal manifestation of Graves’ disease (GD). Similar to GD, TED is caused by an autoimmune response. TED is an autoimmune inflammatory disorder of the orbit and periorbital tissues, characterized by upper eyelid retraction, swelling, redness, conjunctivitis, and bulging eyes. The pathophysiology of TED is complex, with the infiltration of activated T lymphocytes and activation of orbital fibroblasts (OFs) and autoantibodies against the common autoantigen of thyroid and orbital tissues. Better understanding of the multifactorial pathogenesis of TED contributes to the development of more effective therapies. In this review, we present current and potential drug targets. The ideal treatment should slow progression of the disease with as little interference with patient immunity as possible. In the future, TED treatment will target the immune mechanism involved in the disease and will be based on a strategy of restoring tolerance to autoantigens.

show abstract

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry

Hugo

Kojanová

Turkova

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Background Real-world data on the long-term use of guselkumab for treatment of psoriasis are still limited. Objective We aimed to evaluate long-term efficacy, safety, and drug survival of guselkumab in a real-world setting. Methods This is a retrospective study analyzing Czech Republic registry (BIOREP) data of patients treated with guselkumab. Results In total, 333 patients were included. Improvement in Psoriasis Area and Severity Index (PASI) score was significant. Mean PASI score decreased from 16 at baseline to 0.7, 0.9, and 0.8 after 12, 24, and 36 months, respectively. Absolute PASI scores of ≤ 3 and ≤ 1 were achieved in 93.9% and 77.9%, 94.2% and 71.0%, and 94.8% and 70.7% of patients after 12, 24, and 36 months, respectively. Response PASI 90 and PASI 100 were attained in 81.8% and 57.1%, 75.4% and 50.7%, and 75.9% and 55.2% of patients after 12, 24, and 36 months, respectively. The percentage of patients achieving PASI 90 and PASI 100 responses was higher throughout the study in bio-naive and in normal-weight patients, while presence of psoriatic arthritis had no influence. Improvement in Dermatology Life Quality Index (DLQI) score was also significant; mean DLQI score decreased from 14.2 at baseline to 0.9, 1.0, and 0.7 after 12, 24, and 36 months, respectively. Patients with PASI 100 had lower mean DLQI throughout the study compared with patients with PASI 90. Major reason for discontinuation was loss of effectiveness in 7.1% of patients, while only 0.6% were due to adverse events. Overall cumulative drug survival was high, with only a minimal decline over time, reaching 91.6%, 87.0%, and 85.5% after 12, 24, and 36 months, respectively. Drug survival was not affected by previous biological treatment, patient weight, or presence of psoriatic arthritis. Conclusions This real-world study demonstrated the long-term effectiveness, good safety profile, and high drug survival of guselkumab treatment over a period of 36 months.

show abstract

Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study

Cited by 4 publications

References 35 publications

The immunological understanding on germinal center B cells in psoriasis

The immunological understanding on germinal center B cells in psoriasis

Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets

Long-Term Efficacy, Safety, and Drug Survival of Guselkumab in Patients with Psoriasis: Real-World Data from the Czech Republic BIOREP Registry

Contact Info

Product

Resources

About